GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
Time Frame: 2010 and 2016
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Eudra CT-No: 2009-013856-61.
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
German-speaking myeloma multicenter group (GMMG)
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
Leukemia; 2021
731. CLINICAL AUTOLOGOUS TRANSPLANTATION: RESULTS: MULTIPLE MYELOMA: SALVAGE AUTOLOGOUS TRANSPLANTS, MINIMAL RESIDUAL DISEASE, AND CHECKPOINT INHIBITORS| NOVEMBER 29, 2018
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse